Afatinib (BIBW 2992) development in non-small-cell lung cancer.

  title={Afatinib (BIBW 2992) development in non-small-cell lung cancer.},
  author={Vera Hirsh},
  journal={Future oncology},
  volume={7 7},
Afatinib (BIBW 2992), a novel aniline-quinazoline derivative, irreversibly and equipotently targets the intrinsic kinase activity of all active ErbB receptor family members. Preclinical results show that afatinib is effective in lung cancer models, including those with EGF receptor (EGFR) mutations resistant to reversible first-generation EGFR inhibitors. Afatinib is being investigated in the LUX-Lung program, which will evaluate afatinib as a first-line treatment in patients with EGFR… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 26 extracted citations


Publications referenced by this paper.
Showing 1-10 of 39 references

A Phase I dose escalation trial of BIBW 2992, an irreversible EGFR/HER2 kinase inhibitor, for 20 and 13 days in combination with docetaxel every 21 days

  • J Marshall, GI Shapiro, E Terlizzi, P Stopfer, A Amelsberg, M. Gordon
  • Ann. Oncol
  • 2008
Highly Influential
7 Excerpts

towards the systems level

  • A Citri, Yarden Y. EGF–ErbB signalling
  • Nat. Rev. Mol. Cell. Biol. 7, 505–516
  • 2006
Highly Influential
3 Excerpts

A Phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR / HER 1 mutations ( LUX - Lung 2 )

  • W Su
  • Ann . Oncol .
  • 2010

Similar Papers

Loading similar papers…